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Given the growing aged care population, the complexity of their medication-related needs and increased risk of
adverse drug events, there is a necessity to systematically monitor and manage medication-related quality of care.
The aim of this systematic review was to identify and synthesise medication-related quality of care indicators with
respect to application to residential aged care. MEDLINE (Ovid), Psychinfo, CINAHL, Embase and Google® were searched
from 2001 to 2013 for studies that were in English, focused on older people aged 65+ years and discussed the
development, application or validation of original medication-related quality of care indicators. The quality of
selected articles was appraised using the Critical Appraisal Skills Program and psychometric qualities extracted and
synthesised using content analysis. Indicators were mapped to six medication-related quality of care attributes and a
minimum indicator set derived. Thirty three articles describing 25 indicator sets met the inclusion criteria. Thirteen
(52%) contained prescribing quality indicators only. Eight (32%) were developed specifically for aged care. Twenty three
(92%) were validated and seven (28%) assessed for reliability. The most common attribute addressed was medication
appropriateness (n = 24). There were no indicators for evaluating medication use in those with limited life expectancy,
which resulted in only five of the six attributes being addressed. The developed minimum indicator set contains
28 indicators representing 22 of 25 identified indicator sets. Whilst a wide variety of validated indicator sets exist,
none addressed all aspects of medication-related quality of care pertinent to residential aged care. The minimum
indicator set is intended as a foundation for comprehensively evaluating medication-related quality of care in this
setting. Future work should focus on bridging identified gaps.
Keywords: Aged or aged; Over 80; Residential aged care or nursing home; Quality improvement; Quality
indicators; Medication safety and Systematic reviewKey points
 Twenty eight previously validated medication-related
quality of care indicators (minimum indicator set)
were identified as relevant to both the aged care
setting and clinical needs of residents.
 Validated indicators which address appropriate
medication-related care in those with limited life
expectancy are lacking and need to be explored
further.
 The minimum indicator set developed in this study
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in any medium, provided the original work is proutilisation of medication-related quality of care
indicators in the aged care sector.Introduction
In Australia and other developed countries the popula-
tion is ageing rapidly. Since 1970, the Australian popula-
tion has aged significantly with a six-fold increase in the
proportion of adults aged 85 years and older (Australian
Institute of Health and Welfare 2010) with similar statis-
tics reported in the UK, Europe and the USA (Office for
National Statistics. Statistical Bulletin: Older People’s
Day 2011; Howden & Meyer 2011). One consequence of
an ageing population is increased demand on health care
and social support systems. In 2011, 165,000 Australians
lived in permanent aged care (Australian Institute of Health
and Welfare 2012) and it is projected that by 2050 aged
care services will be provided to around 3.5 millionpen Access article distributed under the terms of the Creative Commons
icenses/by/4.0), which permits unrestricted use, distribution, and reproduction
perly credited.
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nancial cost of $1.8% of the GDP (Commonwealth of
Australia 2010).
The prevalence of multiple chronic conditions (multi-
morbidity) in the older population is reported to be
between 65 to 80% (Britt et al. 2008). Multimorbidity is
associated with use of multiple medicines (polypharmacy)
which in turn is linked to medication-related adverse out-
comes including falls, death and hospitalisation (Wilson et
al. 2010; Milton et al. 2008). This is compounded by the
physiologic effects of ageing, such as altered clearance of
medicines (Milton et al. 2008). In the United States
medication-related adverse events in residential aged care
have been estimated to be between 1.19 to 7.26 incidents
per 100 resident-months and for every $1 (US) spent on
medicines in aged care it is estimated $1.33 is spent on
treating adverse events (Bootman et al. 1997).
Given the growing aged care population, the complexity
of their medication-related needs and increased risk of ad-
verse drug events, there is a necessity to systematically
monitor and manage medication-related quality of care.
Quality of care is traditionally evaluated using indicators
which target the most relevant aspects of healthcare (Arah
et al. 2006; Mainz 2003). Whilst there is ongoing construct-
ive debate regarding the relationship between quality of
care indicators and patient outcomes, they remain the gold
standard for evaluating the quality of many aspects of
health care. For example, the National Committee for
Quality Assurance in the USA and the National Institute
for Health and Care Excellence in the United Kingdom
both advocate the use indicators for evaluating quality of
care (National Committee for Quality Assurance & USA:
www.ncqa.org Accessed [September 2013; National
Institute for Health and Care Excellence 2014a). In the
Australian setting, the 2011 Productivity Commission
Inquiry Report, Caring for Older Australians, identified
the need for validated indicators that address the quality
of care in the aged care population, including medication-
related quality of care (Productivity Commission 2011).
Whilst a variety of indicators exist to evaluate the
medication-related quality of care in the ambulatory
elderly, few specifically address the needs of the residen-
tial aged care population. The aged care population is
commonly frailer and more dependent than the ambula-
tory older population and as a consequence has different
medication-related needs. Expectations of health out-
comes may also differ between the two populations due
to differences in quality of life values and life expectancy.
Additionally, many medication-related quality of care
sets are overburdened with dozens of indicators and
minimal direction for prioritising the evaluation process,
minimizing their utilisation in the clinical setting.
The aims of this systematic review were to identify,
describe and consolidate the most appropriate and feasiblyactionable medication-related quality of care indicators for
use in residential aged care and more specifically for
Australian residential aged care.
Methods
Data sources
MEDLINE (Ovid), PsycINFO, Embase and CINAHL
databases were searched between January 2001 to
December 2013. The following search terms (Medical
Subject Headings and keywords) were used for all four
databases: Quality Assurance, Health Care/ or *“Quality
of Health Care”/ or “quality of health care*”.mp.
AND*Quality Indicators, Health Care/ or *“Outcome
and Process Assessment (Health Care)”/ or clinical indica-
tor*.mp. OR prescribing indicator*.mp. OR *Polypharmacy/
or polypharmacy*.mp. OR inappropriate prescribing*.mp.
OR “Quality use of medicine*”.mp. The search was limited
to articles published in English and focusing on older
people aged 65 years and older. Reference lists of eligible
papers were searched to further identify suitable publica-
tions. If an article identified via reference check list was not
published within the pre-defined time frame it was included
if the indicator(s) was currently used in public reporting or
research. ‘Quality in Health care’ was used as the search
term for Google® with the first 100 hits screened to
maximize relevance to the search criteria. Authors’ know-
ledge of government and organisation websites with a
focus on delivery and/or evaluation of health care were
also searched for relevant articles (Websites searched
include AIHW (Australian Institute of Health and
Welfare) (www.aihw.gov.au), Institute for Healthcare
Improvement (www.ihi.org), NPS (National Prescrib-
ing Service) (www.nps.org.au), European Directorate
for the Quality Use of Medicines & Healthcare
(www.edqm.eu), European Society for Quality in
Health care (www.esqh.net), CMS (Centers for Medi-
care and Medicaid Services) (www.cms.gov), Health
Indicators Warehouse (www.healthindicators.gov), NICE
(National Institute for Health and Clinical Excellence)
(www.nice.org.uk), RAND Corporation (www.rand.org),
Cochrane Collaboration (www.cochrane.org) and Emerging
Researchers in Ageing (www.era.edu.au).
The search strategy was developed in consultation
with a librarian specialising in health databases. Methods
for identifying and selecting the articles were predeter-
mined in a protocol developed collaboratively by all
three authors. The reporting of this systematic review
conforms to the PRISMA checklist endorsed by the
Cochrane Collaboration (Moher et al. 2009).
Study selection
Original articles describing the development of an
indicator or set of indicators to assess the quality of care
in the elderly (>65 years) were included if they addressed
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excluded if they: (1) were undertaken in populations
with specific care needs mostly unrelated to the older
population such as paediatrics, oncology, obstetrics and
HIV patients (2) focused on assessing the quality of care
in settings unrelated to aged care such as emergency
care and surgery or (3) discussed the application of, or
adaptation of an existing indicator(s). For example, arti-
cles which discussed the adaption of Beers Criteria to a
country’s pharmacopeia were excluded as this was con-
sidered an adaption of an existing indicator set. Research
involving the amalgamation of several indicator sets was
also excluded. Articles relating to transitional care were
excluded as the focus of this research is not the process
of moving into or out of aged care.
For the purposes of this research a medication-related
quality of care indicator was defined as a ‘measure to be
used as a guide to monitor, evaluate and improve the
direct and indirect aspects of medication use affecting
quality of care and patient outcomes.’ Direct aspects
of medication use include prescribing, administration of
medications and clinical services related to medication
use. Indirect aspects of medication use include organisa-
tional factors and health outcomes.
Reviewers
One author (JH) conducted the initial database search,
the first three sifts of articles, the Google® search and
reference list check. Relevant articles were assessed for
quality using the Critical Appraisal Skills Program
(CASP) criteria by one author (JH) (Critical Appraisal
Skills & United Kingdom: www.casp-uk.net Accessed
[September 2011). All three reviewers (JH, AV and GC)
met to discuss the appropriateness of inclusion of each
article with respect to the inclusion criteria and the
quality of the article. Disagreements were resolved by
discussion. Articles were excluded if they did not meet
all CASP criteria. CASP is recommended by the
Cochrane Collaboration as a simple and effective tool to
analyse the quality of qualitative research (Hannes 2011).
Data extraction and synthesis
Data extraction and synthesis was undertaken in several
stages. Firstly, descriptive qualities were extracted from
each indicator set with an emphasis on medication use,
country of origin, target population and operational
status by one author (JH). Secondly, content analysis
was used to synthesise the psychometric properties of
the indicator sets as it is a systematic, effective and trans-
parent method for categorising data and identifying com-
monalities between qualitative studies (Dixon-Woods et
al. 2005). Whilst there is no standardised way of
categorising quality of care indicators, several key psycho-
metric qualities were identified from the literature (NationalCommittee for Quality Assurance & USA: www.ncqa.org
Accessed [September 2013; Clark & Bierman 2009;
Australian Institute of Health and Welfare 2009). Con-
sumer involvement was added due to its significance to
Australian medicines policy (Department of Health and
Ageing 1999). The final content analysis template was
approved by all authors and systematically applied using a
standardised data collection form by one author (JH). All
authors (JH, AV and GC) met and reviewed the descrip-
tive qualities and content analysis results for each article.
Disagreements were resolved by discussion.
Thirdly, a subsequent search to establish basic oper-
ational status and further validation studies of the
included indicator sets was performed by one author
(JH) in February 2014 using Google® and Google
scholar® with the indicator name.
Definitions of key psychometric properties
The aspect of health care they evaluate: indicators can
be described using a three part inter related hierarchical
structure (Donabedian 1966). Structural indicators evalu-
ate the characteristics of the organisation providing the
care, process indicators evaluate the care that is provided
and outcome indicators evaluate the results of the care
provided.
Type of indicator: explicit indicators are criteria-
based whereas implicit indicators rely more on individ-
ual clinical judgment (Donabedian 1988; Lund et al.
2011; Chang & Chan 2010; Spinewine et al. 2007).
Scientific merit of the indicators: indicators should
measure what they intend to measure (content validity), be
meaningful and relevant to the key audience (face validity)
and identify the same effect when measured at different
times or by different people (reliability) (Martirosyan et al.
2010). Other properties that are useful to demonstrate are
concurrent validity (comparison of indicator to a gold
standard) and predictive validity (the ability of the indicator
to predict a health outcome) (Martirosyan et al. 2010).
Real life application: both external validity (the ability
of the indicator to be applied as effectively to another
health care setting or in another country) and feasibility
(the degree to which the required data can be collected
and reported in a timely manner) describe the practical-
ity of the indicator and can often determine if the indi-
cator is reported (National Committee for Quality
Assurance & USA: www.ncqa.org Accessed [September
2013; Burchett et al. 2011).
Consumer involvement: consumers are central to
Australia’s National Medicines Policy (Department of
Health and Ageing 1999) and should contribute to the
discussion on prioritizing measures to evaluate aspects of
health care rather than relying solely on expert opinion.
Once identified and described each indicator set was
mapped to six of the most relevant medication-related
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aged care. These attributes were derived by all au-
thors (JH, AV and GC) from sentinel papers on qual-
ity of care for the medically complex elderly, known
epidemiology of chronic disease and medication use
in Australian residential aged care and Australian
medicines policy. The initial mapping was undertaken
by one author (JH) and results were reviewed by two
authors (AV and GC). These attributes do not ad-
dress every medication-related quality of care issue
for aged care residents. They are intended to assist
with targeting the most significant issues according
to the available information at the time of this study.
They are intended to focus evaluation of medication-
related QOC on the greatest burden of disease,
greatest medication-related risk factors and relevant
quality of care activities in the aged care population.
This parsimonious approach to selecting indicators
is concordant with the conceptual framework for
developing and implementing health care indicators
as it improves the feasibility of implementation
(Donabedian 1980).Medication-related attributes relevant to Australian
residential aged care
General medication appropriateness: Appropriateness
of medication is a central tenant to many quality of care
models including the Australian quality use of medicines
strategic plan (Australian Institute of Health and
Welfare 2009; Department of Health and Ageing 1999;
Donabedian 1980). Medication appropriateness is de-
fined as the use of a medication only when necessary,
with consideration to an individual’s clinical indications,
co-existing conditions and the risk-benefit profile using
evidenced-based criteria.
There is a growing awareness of the complexity
between managing patient’s multiple chronic diseases
using evidence based guidelines for each condition
and maximising the benefit to the individual (Tinetti
et al. 2004; Tinetti et al. 2012; Gilbert et al. 2011).
This is particularly relevant to the challenges of asses-
sing quality of care in the frail and medically complex
older population, who are commonly excluded from
clinical trials from which evidence based guidelines
are derived. (Holmes et al. 2013; Marengoni 2013).
Attention will be directed to identifying indicators
which attempt to address this gap.
Medication appropriateness for the most prevalent
chronic diseases: The most prevalent diseases in the
Australian aged care population are dementia, car-
diovascular disease (CVD) and musculoskeletal con-
ditions (Australian Institute of Health and Welfare
2012).Medication appropriateness those with limited life
expectancy: The majority of Australian aged care resi-
dents die within three years of admission to residential
care (Australian Institute of Health and Welfare 2012).
Medication should be reconciled with respect to time to
benefit (Holmes et al. 2013).
Detection and monitoring for adverse drug events:
Chart review studies undertaken in Australian resi-
dential aged care reveal that the majority of residents
are exposed to over five medicines per day many of
which are associated with adverse outcomes in the
older population (Somers et al. 2010; Wilson et al.
2011). In 2008, a population based study found that
residents were taking on average nine or more medi-
cines with 50% exposed to psychotropic medication
which are known to be related to adverse events such
as falls (Roughead et al. 2008). Attention will be
directed to indicators which monitor and detect for
adverse drug events.
Access to medication-related services: Australian
aged care residents are entitled to several medication-
related services, such as medication reviews, which may
influence the quality of medication use (Gilbert et al.
2002). These services are an opportunity to modify
prescribing according to the resident’s current clin-
ical condition as well as identifying adverse drug
reactions.
Medication-related quality of care policies: Both in
Australia and overseas, it is recommended that resi-
dential aged care facilities regularly review medication
management policies and procedures as part of their
quality improvement cycle (Department of Health
2012; National Institute for Health and Care Excel-
lence 2014b).
Developing the minimum indicator set
The results from mapping were used to guide the devel-
opment of a minimum indicator set for evaluating
medication-related quality of care in Australian residen-
tial aged care. The objectives were to identify and syn-
thesise the most appropriate indicators with respect to
the core needs of this population (six key medication-
related attributes) which can be feasibly implemented
within the Australian aged care setting to facilitate the
assessment of quality of care.
Individual indicators were included in the minimum
indicator set if they addressed at least one of the six
core medication-related attributes and were present in
three or more of the identified indicator sets. This
represented the most parsimonious balance of address-
ing the majority of attributes without overburdening
the evaluation process. Indicators included in the mini-
mum indicator set also needed to be feasibly collected
and reported at a population level. The minimum
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and reviewed by two authors (AV and GC) and disagree-
ments resolved by discussion.
Results
A total of 33 articles discussing 25 independent indicator
sets were included in the systematic review (see Figure 1
for study selection flowchart). For some indicator sets
more than one article was necessary to describe their
development. Table 1 describes the included indicator
sets grouped according to their emphasis on medication
use and described by country of origin, target population
and current operational status.
Eight of the identified indicator sets are general quality
of care indicator sets which contain at least one
medication-related quality of care indicator (National
Committee for Quality Assurance & USA: www.ncqa.org
Accessed [September 2013; Australian Institute of Health
and Welfare 2009; Campbell Research and Consulting
(CR&C) 2006; Nay et al. 2004; Courtney et al. 2007;Figure 1 Flowchart of the study selection process.Centres for Medicare and Medicaid Services & USA:
www.cms.gov Accessed [February 2014; Wegner et al.
2007; Primary Care & Social Care Information Centre
2013). Four indicator sets focus on medication-related
quality of care and evaluate a range of activities related to
medication use (Department of Health 2012; NSW Thera-
peutic Assessment Group 2007; National Prescribing
Service 2006; Mackinnon & Hepler 2002). Thirteen sets
address prescribing and these are commonly referred to in
the literature as prescribing quality indicators or PQIs
(Basger et al. 2008; Hilmer et al. 2007; Holt et al. 2010;
McLeod et al. 1997; The American Geriatrics Society
2012; Hanlon et al. 1992; Rognstad et al. 2009; Huisman-
Baron et al. 2011; O'Mahony et al. 2010; Winit-Watjana et
al. 2008; Laroche et al. 2007; Rancourt et al. 2004; Onder
et al. 2013). The majority of indicator sets originated from
Australia (n = 8) (Australian Institute of Health and Wel-
fare 2009; Department of Health 2012; Campbell Research
and Consulting (CR&C) 2006; Nay et al. 2004; Courtney
et al. 2007; NSW Therapeutic Assessment Group 2007;
Table 1 Characteristics of identified indicator sets (Country of origin)




Brief description Operational status
Quality of care indicator sets with at least one medication-related quality of care indicator (n = 8)
Resident-centred quality indicators in
residential aged care or The
Campbell Report (Campbell Research
and Consulting (CR&C) (Campbell
Research and Consulting (CR&C)
2006))
Aged care 24 indicators. ‘Prevalence of medication
use’ is the only medication-related
indicator.
Not piloted and not operational
(National Aged Care (National
Aged Care Alliance 2014))
(Australia)
Public Sector Residential Aged Care
Quality of Care Performance
Indicators (Nay et al. 2004)
Aged care 6 indicators. Polypharmacy (9 or more
medications) is the only medication-
related indicator.
The set has been introduced
across the whole of public
service residential aged care
in Victoria. No external reporting
(National Aged Care (National
Aged Care Alliance 2014)).
(Australia)
ResCareQA (Residential Care Quality
Assessment formally the Clinical
Care Indicators Tool or CCI)
(Courtney et al. 2007; Courtney et al.
2011)
Aged care 23 indicators of which two are medication
related. Polypharmacy (9 or more
medications) and medication review.
Piloted (National Aged Care
(National Aged Care Alliance 2014))
and assessed for content validity
(Courtney et al. 2011).
(Australia)
National indicators of safety and
quality in health care (Australian
Institute of Health and Welfare 2009)
All health
care sectors
55 indicators of which 5 relate to aged
care and 1 to medication (annual
medication review). 22 indicators with
potential to evaluate medication-related




relating to some of the indicators
is available in various government
reports.
(Australia)
Minimum Data Set (version 3.0)
Nursing Home Quality Measures.
(Centres for Medicare and Medicaid
Services & USA: www.cms.gov
Accessed [February 2014;
Zimmerman et al. 1995;
Hawes et al. 1997)
Aged care 18 measures covering several aspects of
aged care (derived from Resident
Assessment Instrument-MDS developed
in 1995).Medication-related indicators
include vaccination rates and use of
antipsychotic medications.
Mandated quarterly reporting of
indicators on Centres for Medicare
and Medicaid website. Updated
regularly.
(USA)
Assessing Care of Vulnerable Elders
(version 3) or ACOVE–3





392 indicators covering 26 conditions.
Medication use addressed by 98 indicators
including mediation specific indicators,
medication review rates, continuity of care
and medication list reconciliation.
Extensively reported in the scientific
literature and used as a model for
adaptations in other countries.
Studies and reports available
online.(USA)
Healthcare effectiveness data and
information set or HEDIS (National





83 indicators of which approximately one
third are medication-related indicators
including condition specific (e.g. treatment
of COPD, asthma and diabetes) and general
indicators (e.g. medication review,
post-discharge medication reconciliation
and medications to avoid in the elderly
(Beer’s criteria)).
Approximately 90% of US health
plans report this data voluntarily.
Selected reports available online.
Updated annually.
(USA)
Quality and Outcomes Framework or




Over 140 indicators. Clinical indicators cover
22 clinical areas and contain many medication
related indicators (e.g. appropriate treatment
of hypertension and medication review).
Voluntary annual reporting by




Indicator sets with a primary focus on medication-related quality of care (n = 4)
Guiding principles for medication
management in residential aged care
facilities (Australia) (Department of
Health 2012)
Aged care 17 guiding principles covering governance,
prescribing, medication administration,
medication storage and evaluating practice.
Released 2012. Not operational.
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Table 1 Characteristics of identified indicator sets (Country of origin) (Continued)
Indicators for Quality Use of Medicines
in Australian Hospitals (NSW
Therapeutic Assessment Group 2007)
(Australia)
Hospital 30 indicators covering prescribing,
medication monitoring and medicine
education.
Not operational.
Indicators for Quality Prescribing in
Australian General Practice (National
Prescribing Service 2006) (Australia)
General
practice
21 indicators covering prescribing,
monitoring, education and review of
medications.
Not operational.
Preventable Drug Related Morbidity (PDRM)
(Mackinnon & Hepler 2002; Robertson &
MacKinnon 2002; Morris et al. 2002) (Canada
and USA)
Geriatric 52 indicators identifying health care
utilisation due to inappropriate or
failure to use medications. Each
indicator explicitly states a pattern
of care and the resulting outcome.
Reported in scientific literature.
Indicator sets addressing prescribing (PQIs) (n = 13)
Australian Prescribing Indicators Tool (Basger
et al. 2008) (Australia)
General
Practice
48 prescribing indicators for patients
65 years or older. Focus is on drug-drug
and drug-disease interactions.
Reported in scientific literature.
Drug Burden Index or DBI (Hilmer et al. 2007) General
Practice
A patented formula for calculating the
total sedative and anticholinergic load
in an individual.
Reported in scientific literature.
(USA)
The PRISCUS List (Holt et al. 2010) Geriatric
Prescribing
83 potentially inappropriate medications
in the elderly (> = 65 years) with
recommendations and alternatives.
Reported in scientific literature.
(Germany)
Inappropriate Prescribing in the Elderly Tool or
IPET (McLeod et al. 1997; Naugler et al. 2000)
Hospital Originally the McLeod criteria, adapted in
2000 to the IPET which has 14 inappropriate
prescribing indicators.
Reported in scientific literature.
(Canada)






Original set of indicators from 1991, last
updated 2012. 53 recommendations for
medications to be avoided in the elderly
(> = 65) or avoided in elderly with certain
conditions/medications.
Reported extensively in the
scientific literature and used in
the HEDIS dataset (Marcum
& Hanlon 2012).(USA)
Medication Appropriateness Index or MAI
(Hanlon et al. 1992)
General
Practice
Classifies appropriateness of each medication
against ten criteria.
Reported in scientific literature.
(USA)
NORGEP criteria for assessing inappropriate




36 criteria assessing use of particular
medications and drug combinations in the
70+ population.
Reported in scientific literature.
(Norway)
Criteria for drug selection in frail elderly
patients (Huisman-Baron et al. 2011)
Frail elderly 23 criteria to assess individual drug classes
in the frail elderly.
Reported in scientific literature.
(Netherlands)
The Screening tool of Older Person’s
Prescriptions (STOPP) and Screening Tool to




22 START (address under prescribing) and
65 STOPP (address inappropriate prescribing)
criteria.
Extensively reported in the
literature and currently used in
an international database trial
(The SENATOR Project & Europe:
www.senator-project.eu
Accessed [February 2014).
(O'Mahony et al. 2010; Barry et al. 2007;
Gallagher & O'Mahony 2008)
(Ireland)
Criteria for high-risk medication use
(Winit-Watjana et al. 2008)




Potentially inappropriate medications in




36 indicators covering medications to avoid
and medications to avoid in certain conditions
in the elderly.
Reported in scientific literature
(France)
Potentially inappropriate prescriptions for older
patients in long-term care or PIP (Rancourt
et al. 2004)
Aged care 111 prescribing indicators covering inappropriate
medication, duration, dosage and medication
combinations.
Reported in scientific literature
(Canada)
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Table 1 Characteristics of identified indicator sets (Country of origin) (Continued)
CRIteria to assess appropriate Medication
use among Elderly complex patients




19 recommendations addressing treating
older complex patients with at least one
of the following chronic disease: diabetes,
hypertension, congestive heart failure, atrial
fibrillation and coronary artery disease.
Currently undergoing validation for
clinical outcomes.
(Italy)
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the USA (n = 6) (National Committee for Quality Assur-
ance & USA: www.ncqa.org Accessed [September 2013;
Centres for Medicare and Medicaid Services & USA:
www.cms.gov Accessed [February 2014; Wegner et al.
2007; Hilmer et al. 2007; The American Geriatrics Society
2012; Hanlon et al. 1992).
Eight of the indicator sets were developed specifically
for aged care. Two of these eight addressed several aspects
of medication-related quality of care (e.g. prescribing,
medication review, consumer counseling, medication
reconciliation) (Department of Health 2012; Wegner et al.
2007). Three included one or more of the following
medication-related quality of care indicators: polyphar-
macy, prevalence of medication use and medication
review (Campbell Research and Consulting (CR&C)
(Campbell Research and Consulting (CR&C) 2006); (Nay
et al. 2004; Courtney et al. 2007)) and the remaining three
indicator sets developed for residential aged care con-
tained PQIs (Centres for Medicare and Medicaid Services
& USA: www.cms.gov Accessed [February 2014; The
American Geriatrics Society 2012; Rancourt et al. 2004).
Three indicator sets are currently systematically exter-
nally reported (National Committee for Quality Assurance
& USA: www.ncqa.org Accessed [September 2013;
Centres for Medicare and Medicaid Services & USA:
www.cms.gov Accessed [February 2014; Primary Care &
Social Care Information Centre 2013). Sixteen of the indi-
cator sets have or are undergoing further validation stud-
ies and/or subsets of their dataset have been reported
elsewhere (Nay et al. 2004; Courtney et al. 2007; Wegner
et al. 2007; Basger et al. 2008; Hilmer et al. 2007; Holt et
al. 2010; McLeod et al. 1997; The American Geriatrics So-
ciety 2012; Hanlon et al. 1992; Rognstad et al. 2009;
Huisman-Baron et al. 2011; O'Mahony et al. 2010;
Laroche et al. 2007; Rancourt et al. 2004; Onder et al.
2013; Robertson & MacKinnon 2002). No evidence of
further validation, use or reporting was found for six
indicator sets (Australian Institute of Health and
Welfare 2009; Department of Health 2012; Campbell
Research and Consulting (CR&C) 2006; NSW Thera-
peutic Assessment Group 2007; National Prescribing
Service 2006; Winit-Watjana et al. 2008).
Content analysis
The psychometric properties of the identified indicators
sets are listed in Table 2. Nineteen (76%) of the indicatorsets contained only process indicators (Campbell Research
and Consulting (CR&C) 2006; Nay et al. 2004; Courtney
et al. 2007; Centres for Medicare and Medicaid Services &
USA: www.cms.gov Accessed [February 2014; Wegner et
al. 2007; NSW Therapeutic Assessment Group 2007;
Basger et al. 2008; Hilmer et al. 2007; Holt et al. 2010; The
American Geriatrics Society 2012; Hanlon et al. 1992;
Rognstad et al. 2009; Huisman-Baron et al. 2011;
O'Mahony et al. 2010; Winit-Watjana et al. 2008;
Laroche et al. 2007; Rancourt et al. 2004; Onder et al.
2013; Naugler et al. 2000) and the majority of these
(n = 13) were PQIs. Only one indicator set included
medication-related outcome indicators, the prevent-
able drug-related morbidity (PDRM) indicator set,
which had over fifty medication-related outcome indi-
cators (Mackinnon & Hepler 2002). Five sets con-
tained a combination of structural, process and
outcome indicators (National Committee for Quality
Assurance & USA: www.ncqa.org Accessed [Septem-
ber 2013; Australian Institute of Health and Welfare
2009; Department of Health 2012; Primary Care &
Social Care Information Centre 2013; National Pre-
scribing Service 2006). The majority (80%) included
only explicit indicators (National Committee for
Quality Assurance & USA: www.ncqa.org Accessed
[September 2013; Australian Institute of Health and
Welfare 2009; Campbell Research and Consulting
(CR&C) 2006; Nay et al. 2004; Courtney et al. 2007;
Centres for Medicare and Medicaid Services & USA:
www.cms.gov Accessed [February 2014; Wegner et al.
2007; Primary Care & Social Care Information Centre
2013; NSW Therapeutic Assessment Group 2007; Na-
tional Prescribing Service 2006; Mackinnon & Hepler
2002; Hilmer et al. 2007; Holt et al. 2010; The Ameri-
can Geriatrics Society 2012; Rognstad et al. 2009;
O'Mahony et al. 2010; Winit-Watjana et al. 2008;
Laroche et al. 2007; Rancourt et al. 2004; Naugler et
al. 2000) and 92% were developed through extensive
literature reviews and expert consensus methods,
which implies both face and content validity. Com-
mon methodologies used to achieve consensus were
the Delphi method, which uses consecutive rounds of
anonymous consultation to achieve group consensus,
and expert panels. Reliability was tested in seven of the in-
dicator sets (National Committee for Quality Assurance &
USA: www.ncqa.org Accessed [September 2013; Centres
for Medicare and Medicaid Services & USA: www.cms.gov
Table 2 Content analysis results for identified indicator
sets
Initial validation (Please note references may refer to original article or
article(s) discussing subsequent validation)
Key characteristic Number (%)
Health care aspect (structural,
process and outcome)*
19 (76%) process (Campbell Research
and Consulting (CR&C) (Campbell
Research and Consulting (CR&C) 2006;
Nay et al. 2004; Courtney et al. 2007;
Wegner et al. 2007; NSW Therapeutic
Assessment Group 2007; Basger et al.
2008; Hilmer et al. 2007; Holt et al. 2010;
Hanlon et al. 1992; Rognstad et al. 2009;
Huisman-Baron et al. 2011; O'Mahony
et al. 2010; Winit-Watjana et al. 2008;
Laroche et al. 2007; Rancourt et al. 2004;
Onder et al. 2013; Naugler et al. 2000))
1 (4%) outcome (Mackinnon & Hepler
2002)
5 (20%) combination (National
Committee for Quality Assurance & USA:
www.ncqa.org Accessed [September
2013; Australian Institute of Health and
Welfare 2009; Department of Health
2012; Primary Care & Social Care
Information Centre 2013; National
Prescribing Service 2006)
Explicit or implicit* 20(80%) explicit ((National Committee
for Quality Assurance & USA:
www.ncqa.org Accessed [September
2013; Australian Institute of Health and
Welfare 2009); Campbell Research and
Consulting (CR&C) (Campbell Research
and Consulting (CR&C) 2006; Nay et al.
2004; Courtney et al. 2007; Centres for
Medicare and Medicaid Services & USA:
www.cms.gov Accessed [February 2014;
Wegner et al. 2007; Primary Care &
Social Care Information Centre 2013;
NSW Therapeutic Assessment Group
2007; National Prescribing Service 2006;
Mackinnon & Hepler 2002; Hilmer et al.
2007; Holt et al. 2010; The American
Geriatrics Society 2012; Rognstad et al.
2009; O'Mahony et al. 2010; Winit-
Watjana et al. 2008; Laroche et al. 2007;
Rancourt et al. 2004; Naugler et al.
2000))
3 (12%) implicit (Department of Health
2012; Hanlon et al. 1992; Huisman-Baron
et al. 2011)
2 (8%) combination(Basger et al. 2008;
Onder et al. 2013)
Validity and reliability 23 (92%) developed via literature review
and consensus methods except DBI
(Hilmer et al. 2007) and the Australian
Prescribing Indicators Tool (Basger et al.
2008)
7 (28%) tested for reliability (National
Committee for Quality Assurance & USA:
www.ncqa.org Accessed [September
2013; Centres for Medicare and
Medicaid Services & USA: www.cms.gov
Accessed [February 2014; NSW
Therapeutic Assessment Group 2007;
National Prescribing Service 2006; The
Table 2 Content analysis results for identified indicator
sets (Continued)
American Geriatrics Society 2012; Hanlon
et al. 1992; Naugler et al. 2000)
Real life application
(transferability and feasibility)
8 (32%) tested for feasibility (National
Committee for Quality Assurance & USA:
www.ncqa.org Accessed [September
2013; Courtney et al. 2007; NSW
Therapeutic Assessment Group 2007;
National Prescribing Service 2006; The
American Geriatrics Society 2012; Hanlon
et al. 1992; O'Mahony et al. 2010;
Naugler et al. 2000)
Consumer involvement 7 (28%)((Australian Institute of Health
and Welfare 2009; Department of Health
2012); Campbell Research and
Consulting (CR&C) (Campbell Research
and Consulting (CR&C) 2006; Nay et al.
2004; Centres for Medicare and
Medicaid Services & USA: www.cms.gov
Accessed [February 2014; Primary Care &
Social Care Information Centre 2013;
National Prescribing Service 2006))
Subsequent validation (post development)
Validity 5 (20%) tested for predictive validity
(Spinewine et al. 2007; Hamilton et al.
2011; Wilson et al. 2012; Frazier 2005)
5 (20%) tested for concurrent validity
(Hamilton et al. 2011; Luo et al. 2012)
Real life application (external
validity and feasibility)
6 (24%) used in different countries or
setting (Gallagher et al. 2011; Askari
et al. 2012; Hanlon & Schmader 2013;
Fiona 2011)
3 (12%) routinely externally reported
(National Committee for Quality
Assurance & USA: www.ncqa.org
Accessed [September 2013; Centres for
Medicare and Medicaid Services & USA:
www.cms.gov Accessed [February 2014;
Primary Care & Social Care Information
Centre 2013)
(*refers to the medication-related quality of care indicators only).
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Group 2007; National Prescribing Service 2006; The
American Geriatrics Society 2012; Hanlon et al. 1992;
Naugler et al. 2000). Feasibility, usually in the form of
piloting was undertaken for eight of the indicator sets
(National Committee for Quality Assurance & USA:
www.ncqa.org Accessed [September 2013; Courtney et al.
2007; NSW Therapeutic Assessment Group 2007; Na-
tional Prescribing Service 2006; The American Geriatrics
Society 2012; Hanlon et al. 1992; O'Mahony et al. 2010;
Naugler et al. 2000). Consumers were involved in the
development process for seven of the indicator sets
(Australian Institute of Health and Welfare 2009;
Department of Health 2012; Campbell Research and
Consulting (CR&C) 2006; Nay et al. 2004; Centres for
Medicare and Medicaid Services & USA: www.cms.gov
Accessed [February 2014; Primary Care & Social Care
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2006) five of which were Australian.
Many of the indicator sets have been further validated
through application in research and reporting. Five indi-
cators sets have been specifically assessed for their asso-
ciation (predictive validity) with health outcomes. These
are the Beer’s criteria, Inappropriate Prescribing in the
Elderly Tool (IPET), Medication Appropriateness Index
(MAI), Drug Burden Index (DBI) and the Screening
Tool of Older Person’s Prescriptions (STOPP) indicators.
A review of Beer’s criteria, IPET and MAI found results
ranging from a positive association with a higher risk of
death, adverse drug reactions and health service utilisa-
tion to no association with mortality and hospital admis-
sions (Spinewine et al. 2007). STOPP indicators have
recently been significantly associated with preventable
medication-related hospitalizations (Hamilton et al.
2011). No association between the DBI and mortality in
older residential aged care residents has been reported
(Wilson et al. 2012). Polypharmacy is used as an indica-
tor of medication-related quality of care in several of the
identified indicator sets and this has been associated
with an increased risk of adverse events such as hospital-
isation and death (Frazier 2005).
Concurrent validity has been examined for five indicator
sets. A study compared the sensitivity and feasibility of the
Beer’s criteria, IPET, Healthcare Effectiveness Data and In-
formation Set (HEDIS) and the MAI and demonstrated an
inverse relationship between ease of application (in terms
of time and resources) and comprehensiveness (Luo et al.
2012). The MAI was found to be the most comprehensive
and time consuming. HEDIS was reported as the simplest
approach but less sensitive to detecting inappropriate
prescribing (Luo et al. 2012). A study comparing the
STOPP and Beer’s criteria found that the STOPP criteria
were more sensitive to detecting potentially inappropriate
medications and associated hospital admissions than
Beer’s criteria (Hamilton et al. 2011).
In terms of external validity, the Beer’s criteria,
STOPP/Screening Tool to Alert to Right Treatment
(START) criteria, Assessing Care of Vulnerable Elders
(ACOVE) indicators and MAI have been applied to
many health care settings (often with minor adaptations)
and in different countries with varying results (Gallagher
et al. 2011; Askari et al. 2012; Hanlon & Schmader
2013). The Quality and Outcomes Framework indicators
were applied to aged care residents (Fiona 2011) and
found poor quality of care.
The three indicator sets which are routinely externally
reported (Minimum Dataset (MDS), HEDIS and Quality
and Outcomes Framework) are reviewed regularly for
clinical validity and reliability (National Committee for
Quality Assurance & USA: www.ncqa.org Accessed
[September 2013; Centres for Medicare and MedicaidServices & USA: www.cms.gov Accessed [February 2014;
Primary Care & Social Care Information Centre 2013)
and demonstrate feasibility on a large scale.Relevance to medication-related quality of care needs for
Australian residential aged care (minimum indicator set)
Presence of indicators which address one or more of the
pre-determined six medication-related attributes is shown
in Table 3, for each of the 25 indicator sets. Approximately
half of the sets (n = 12) addressed medication use in the
most prevalent chronic diseases (National Committee for
Quality Assurance & USA: www.ncqa.org Accessed
[September 2013; Australian Institute of Health and
Welfare 2009; Wegner et al. 2007; Primary Care &
Social Care Information Centre 2013; NSW Thera-
peutic Assessment Group 2007; National Prescribing
Service 2006; Mackinnon & Hepler 2002; Basger et al.
2008; The American Geriatrics Society 2012; O'Mah-
ony et al. 2010; Onder et al. 2013; Naugler et al.
2000). Twenty four indicator sets addressed general
medication appropriateness and eight addressed (dir-
ectly or indirectly) detection of medication-related
adverse events, namely falls (National Committee for
Quality Assurance & USA: www.ncqa.org Accessed
[September 2013; Australian Institute of Health and
Welfare 2009; Campbell Research and Consulting
(CR&C) 2006; Courtney et al. 2007; Centres for Medi-
care and Medicaid Services & USA: www.cms.gov
Accessed [February 2014; Wegner et al. 2007; NSW
Therapeutic Assessment Group 2007; Mackinnon &
Hepler 2002). Seven assessed medication-related ser-
vices (National Committee for Quality Assurance &
USA: www.ncqa.org Accessed [September 2013;
Australian Institute of Health and Welfare 2009;
Department of Health 2012; Courtney et al. 2007;
Wegner et al. 2007; Primary Care & Social Care In-
formation Centre 2013; National Prescribing Service
2006) and four addressed medication policy (Depart-
ment of Health 2012; Wegner et al. 2007; Primary
Care & Social Care Information Centre 2013; Na-
tional Prescribing Service 2006). Two indicator sets
(Assessing Care of Vulnerable Elders (ACOVE) and
CRIteria to assess appropriate Medication use among
Elderly complex patients (CRIME)) addressed review
of medication with respect to limited life expectancy
(O'Mahony et al. 2010; Onder et al. 2013).
Table 4 shows the selected indicators, derived from
the mapping results in Table 3, to define a minimum
indicator set for evaluating medication-related care in
Australian residential aged care. In total 28 individual
indicators were identified which address five of the six
attributes. Twenty two of the 25 indicator sets are repre-
sented in the minimum dataset.
Table 3 Mapping of identified indicator sets to core medication-related criteria


























in residential aged care or The
Campbell Report (Campbell
Research and Consulting (CR&C)
(Campbell Research and Consulting
(CR&C) 2006))
- - + + - -
Public Sector Residential Aged Care
Quality of Care Performance
Indicators (Nay et al. 2004)
- - + + - -
Clinical Care Indicators Tool or CCI
or Uniting Care Clinical Care
Indicators (Courtney et al. 2007;
Courtney et al. 2010)
- - + + + -
National indicators of safety and
quality in health care (Australian
Institute of Health and Welfare
2009)
+ - + + + -
Minimum Data Set (version 3.0)
Nursing Home Quality measures
(Centres for Medicare and Medicaid
Services & USA: www.cms.gov
Accessed [February 2014;
Zimmerman et al. 1995; Hawes
et al. 1997)
- - + + - -
Assessing Care of Vulnerable Elders
(version 3) or ACOVE–3 (Wegner
et al. 2007) (USA)
+ - + + + +
Healthcare effectiveness data and
information set or HEDIS (National
Committee for Quality Assurance &
USA: www.ncqa.org Accessed
[September 2013)
+ - + + + -
Quality and Outcomes Framework
or QOF (Primary Care & Social Care
Information Centre 2013)
+ - + - + +
Guiding principles for medication
management in residential aged
care facilities (Department of
Health 2012)
- - - - + +
Indicators for Quality Use of
Medicines in Australian Hospitals
(NSW Therapeutic Assessment
Group 2007)
+ - + - - -
Indicators for Quality Prescribing in
Australian General Practice
(National Prescribing Service 2006)
+ - + - + +
Preventable Drug Related Morbidity
(PDRM) (Mackinnon & Hepler 2002;
Robertson & MacKinnon 2002;
Morris et al. 2002)
+ - + + - -
Australian Prescribing Indicators
Tool (Basger et al. 2008)
+ - + - - -
Drug Burden Index or DBI (Hilmer
et al. 2007)
- - + - - -
The PRISCUS List (Holt et al. 2010) - - + - - -
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Table 3 Mapping of identified indicator sets to core medication-related criteria (Continued)
Inappropriate Prescribing in the
Elderly Tool or IPET (McLeod et al.
1997; Naugler et al. 2000)
+ - + - - -
Beer’s criteria (The American
Geriatrics Society 2012)
+ - + - - -
Medication Appropriateness Index
or MAI (Hanlon et al. 1992)
- - + - - -
NORGEP criteria for assessing
inappropriate prescriptions to
elderly patients (Rognstad et al.
2009)
- - + - - -
Criteria for drug selection in frail
elderly patients (Huisman-Baron
et al. 2011)
- - + - - -
Screening Tool of Older Person’s
Prescriptions (STOPP) and
Screening Tool to Alert to Right
Treatment (START) (O'Mahony et al.
2010; Barry et al. 2007; Gallagher &
O'Mahony 2008)
+ + + - - -
Criteria for high-risk medication use
(Winit-Watjana et al. 2008)
- - + - - -
Potentially inappropriate
medications in the elderly: a French
consensus panel (Laroche et al.
2007)
- - + - - -
Potentially Inappropriate
Prescriptions for older patients in
long-term care or PIP (Rancourt
et al. 2004)
- - + - - -
CRIteria to assess appropriate
Medication use among Elderly
complex patients or CRIME criteria
(Onder et al. 2013)
+ + + - - -
Table 4 Minimum indicator set for evaluating medication-related quality of care in Australian residential aged care
Core criteria addressed Indicator
1. Medication appropriateness in the
most prevalent diseases
1.1 Use of beta blocker post myocardial infarction/ischaemic heart disease (National Committee for Quality
Assurance & USA: www.ncqa.org Accessed [September 2013; Australian Institute of Health and Welfare
2009; Wegner et al. 2007; Primary Care & Social Care Information Centre 2013; NSW Therapeutic Assessment
Group 2007; National Prescribing Service 2006; Basger et al. 2008)
1.2 Use of statin post myocardial infarction/ischaemic heart disease (Australian Institute of Health and
Welfare 2009; Wegner et al. 2007; Primary Care & Social Care Information Centre 2013; NSW Therapeutic
Assessment Group 2007; National Prescribing Service 2006; O'Mahony et al. 2010)
1.3 Angiotensin converting enzyme inhibitor/angiotensin receptor blocker use in hypertension/congestive
heart failure (Wegner et al. 2007; Primary Care & Social Care Information Centre 2013; NSW Therapeutic
Assessment Group 2007; National Prescribing Service 2006; Mackinnon & Hepler 2002; Basger et al. 2008;
O'Mahony et al. 2010)
1.4 Antiplatelet therapy post myocardial infarction/ischaemic heart disease (e.g. aspirin/clopidogrel not
ticlopidine) (National Committee for Quality Assurance & USA: www.ncqa.org Accessed [September 2013;
Australian Institute of Health and Welfare 2009; Wegner et al. 2007; Primary Care & Social Care Information
Centre 2013; NSW Therapeutic Assessment Group 2007; National Prescribing Service 2006; Basger et al.
2008)
1.5 Antiplatelet therapy post stroke/transient ischaemic attacks (e.g. aspirin/clopidogrel not ticlopidine)
(Wegner et al. 2007; Primary Care & Social Care Information Centre 2013; NSW Therapeutic Assessment
Group 2007; Basger et al. 2008; O'Mahony et al. 2010)
1.6 Medicines to avoid in patients with cardiovascular disease (e.g. NSAIDs/COX 2 inhibitors, calcium
channel blockers and select anti-arrhythmics) (Wegner et al. 2007; Mackinnon & Hepler 2002; Basger et al.
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Table 4 Minimum indicator set for evaluating medication-related quality of care in Australian residential aged care
(Continued)
2008; The American Geriatrics Society 2012; O'Mahony et al. 2010; Winit-Watjana et al. 2008; Naugler et al.
2000)
1.7 Medicines to avoid in patients with dementia (e.g. medications with clinically significant anticholinergic
properties) (Wegner et al. 2007; Basger et al. 2008; The American Geriatrics Society 2012; O'Mahony et al.
2010; Laroche et al. 2007; Onder et al. 2013)
2. Medication appropriateness in
limited life expectancy
Did not meet inclusion criteria
3. General medication appropriateness 3.1 Medicines to avoid in patients at risk of falling or with a history of falls ( e.g. medications with clinically
significant anticholinergic properties, sedating antihistamines, tricyclic antidepressants, monoamine oxidase
inhibitors, selective serotonin reuptake inhibitors, benzodiazepines and antipsychotics) (Wegner et al. 2007;
Mackinnon & Hepler 2002; Basger et al. 2008; The American Geriatrics Society 2012; Rognstad et al. 2009;
O'Mahony et al. 2010)
3.2 Avoid use of benzodiazepines (short and long acting) (Wegner et al. 2007; National Prescribing Service
2006; Basger et al. 2008; Holt et al. 2010; The American Geriatrics Society 2012; Rognstad et al. 2009;
O'Mahony et al. 2010; Winit-Watjana et al. 2008; Laroche et al. 2007; Rancourt et al. 2004; Naugler et al.
2000)
3.3 Avoid use of medicines with clinically significant anticholinergic properties (Wegner et al. 2007; Basger
et al. 2008; Holt et al. 2010; The American Geriatrics Society 2012; Rognstad et al. 2009; O'Mahony et al.
2010; Winit-Watjana et al. 2008; Laroche et al. 2007; Naugler et al. 2000)
3.4 Anti-arrhythmic medicines to avoid (e.g. disopyramide and see 1.6) (The American Geriatrics Society
2012; Rognstad et al. 2009; Laroche et al. 2007; Naugler et al. 2000)
3.5 Digoxin > 0.125mcg/day (The American Geriatrics Society 2012; O'Mahony et al. 2010; Winit-Watjana
et al. 2008; Laroche et al. 2007; Rancourt et al. 2004; Naugler et al. 2000)
3.6 Antidepressants to avoid (e.g. tricyclic antidepressants (see 3.1 and 3.3) and monoamine oxidase
inhibitors (see 3.1) (Wegner et al. 2007; Holt et al. 2010; The American Geriatrics Society 2012; Rognstad
et al. 2009; O'Mahony et al. 2010; Winit-Watjana et al. 2008; Rancourt et al. 2004; Naugler et al. 2000)
3.7 Avoid typical (see 3.3) and atypical antipsychotics (e.g. olanzapine and clozapine) (Holt et al. 2010; The
American Geriatrics Society 2012; Rognstad et al. 2009; O'Mahony et al. 2010; Winit-Watjana et al. 2008;
Rancourt et al. 2004)
3.8 Antispasmodics and muscle relaxants to avoid ( smooth muscle relaxants alverine and mebeverine and
see 3.3) (McLeod et al. 1997; Moher et al. 2009; National Aged Care Alliance 2014; National Committe for
Quality Assurance. (Desirable attributes of HEDIS). USA: www.ncqa.org/tabid/415/Default.aspx Accessed
[March 2012; National Committee for Quality Assurance & USA: www.ncqa.org Accessed [September 2013;
National Institute for Health and Care Excellence 2014a; Onder et al. 2013)
3.9 Avoid duplication of drug class (e.g. >2 NSAIDs) (Mackinnon & Hepler 2002; O'Mahony et al. 2010;
Winit-Watjana et al. 2008; Laroche et al. 2007; Rancourt et al. 2004)
3.10 Avoid alpha blockers (e.g. prazosin and doxazosin) (Holt et al. 2010; The American Geriatrics Society
2012; O'Mahony et al. 2010; Winit-Watjana et al. 2008)
3.11 Avoid centrally acting alpha agonists (e.g. clonidine and methyldopa) (Holt et al. 2010; The American
Geriatrics Society 2012; Laroche et al. 2007; Rancourt et al. 2004; Naugler et al. 2000)
3.12 Calcium channel blockers to avoid (e.g. short acting nifedipine) (Holt et al. 2010; The American
Geriatrics Society 2012; Winit-Watjana et al. 2008; Laroche et al. 2007; Naugler et al. 2000)
3.13 Avoid combination of warfarin and aspirin (+/− gastric protection) (Rognstad et al. 2009; O'Mahony
et al. 2010; Winit-Watjana et al. 2008; Rancourt et al. 2004)
3.14 Avoid ‘Triple Whammy’ combination of angiotensin converting enzyme inhibitor/angiotensin two
receptor antagonist plus diuretic plus non-steroidal anti-inflammatory (excluding low dose aspirin) (National
Prescribing Service 2006; Basger et al. 2008; Rognstad et al. 2009)
3.15 Influenza vaccination rates (National Committee for Quality Assurance & USA: www.ncqa.org Accessed
[September 2013; Australian Institute of Health and Welfare 2009; Centres for Medicare and Medicaid
Services & USA: www.cms.gov Accessed [February 2014; Wegner et al. 2007; Primary Care & Social Care
Information Centre 2013; Basger et al. 2008)
3.16 Pneumococcal vaccinations rates (National Committee for Quality Assurance & USA: www.ncqa.org
Accessed [September 2013; Australian Institute of Health and Welfare 2009; Centres for Medicare and
Medicaid Services & USA: www.cms.gov Accessed [February 2014; Wegner et al. 2007; Basger et al. 2008)
4. Detection and monitoring of
adverse events
4.1 Fall rates (+/− associated with medication use) (Australian Institute of Health and Welfare 2009;
Campbell Research and Consulting (CR&C) 2006; Nay et al. 2004; Courtney et al. 2007; Centres for Medicare
and Medicaid Services & USA: www.cms.gov Accessed [February 2014; Wegner et al. 2007; Mackinnon &
Hepler 2002; Onder et al. 2013)
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Table 4 Minimum indicator set for evaluating medication-related quality of care in Australian residential aged care
(Continued)
5. Access to services 5.1 Annual cycle of care for people with chronic disease (e.g. diabetes) (National Committee for Quality
Assurance & USA: www.ncqa.org Accessed [September 2013; Australian Institute of Health and Welfare
2009; Wegner et al. 2007; Primary Care & Social Care Information Centre 2013)
5.2 Medication review (National Committee for Quality Assurance & USA: www.ncqa.org Accessed
[September 2013; Australian Institute of Health and Welfare 2009; Department of Health 2012; Courtney
et al. 2007; Wegner et al. 2007; Primary Care & Social Care Information Centre 2013; National Prescribing
Service 2006)
6. Policy/Procedure 6.1 Access to up to date medicines information for providers, carers and residents (Department of Health
2012; Wegner et al. 2007; National Prescribing Service 2006)
6.2 Policy of regular medication review including over the counter and complementary medicines
(Department of Health 2012; Wegner et al. 2007; Primary Care & Social Care Information Centre 2013;
National Prescribing Service 2006)
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In this study we identified 25 sets of medication-related
quality of care indicators relevant to residential aged
care. From these, 28 indicators that address key
medication-related quality of care issues specific for resi-
dential aged care were selected to form the minimum
indicator set. All 28 indictors have been previously validated
for face and content validity through either extensive litera-
ture reviews and or expert consensus. Furthermore, exter-
nal validity was demonstrated across countries for some of
these indicators. Indicators for assessment of medica-
tion appropriateness, PQIs, were common among the
identified indicators sets which demonstrated a strong
international consensus on the appropriateness of
these medications use in the elderly. Indicators for
addressing the medication appropriateness for the
most prevalent diseases, detecting and monitoring
adverse drug events, access to relevant services and
medication-related policy were identified in at least
three of the included indicators sets. Indicators to
address medication use in limited life expectancy in
aged care residents are lacking.
Two of the identified indicator sets developed specific-
ally for aged care take quite an extensive approach to
medication management. ACOVE-3 contains nearly 400
indicators with one quarter of the indicators related to
medication use (Wegner et al. 2007). This indicator set
addresses prescribing, monitoring of medicines and
consumer involvement in medication management. It
has been extended to several subsets of indicators such
as quality of care in dementia and poor prognosis. The
Australian Guiding Principles for Medication Manage-
ment in Residential Aged Care has a broad approach to
evaluating medication use ranging from reviewing medi-
cines policies and procedures to annual medication review
but does not target specific medications (Department of
Health 2012). Twelve of the indicators in our minimum
indicator set are from ACOVE-3 and three are from the
Australian Guiding Principles for Medication Manage-
ment in Residential Aged Care. This demonstrates therelevance of these indicators for evaluating medication-
related quality of care in Australian residential aged care.
Whilst ACOVE-3 is a very comprehensive indicator set, it
is burdensome for implementing in a clinical setting with
98 indicators relating to medication-related quality of care,
many of which address clinical conditions not prevalent in
the residential Australian aged care population. Currently
quality of care indicator sets developed specifically for
Australian residential aged care include simplistic
medication-related quality of care indicators such as
polypharmacy and medication review (Table 1). These
two indicators are useful tools for identifying residents at
risk of inappropriate medication-related quality of care
and predicting adverse health outcomes however they do
not reflect the complexity of medication-related care for
the residential aged care population (Duerden et al. 2013).
The minimum indicator set developed in this study pro-
vides a platform for a quality of care indicator set specific
for Australian residential aged care that focuses on the key
requirements to examine medication-related quality of
care in this setting.
The overwhelming majority of medication-related
quality of care indicator sets identified included exclu-
sively PQIs. PQIs play an important role in evaluating
medication-related quality of care. They are evidence
based and specifically target medications known to cause
adverse effects. Furthermore, the PQI sets developed for
the older age groups address medicines most problem-
atic in this population. PQI sets are often criticised due
to their lack of sensitivity as they are designed to be
generically applied across a population and do not
consider variability in individual patient medical needs
and preferences (Spinewine et al. 2007; Steinman et al.
2007). This however enhances the feasibility in reporting
of these indicators. These qualities of PQIs are reflected
by their prevalence in the minimum indicator set. Some
PQI sets target medications to be avoided in certain co-
morbid states (e.g. Beer's criteria) and others (e.g. CRIME)
addressed medication use in clinically complex frail elderly
patients (Onder et al. 2013).
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sumers in the development, however an indicator set with
a more holistic approach to medication-management in
the frail elderly with respect to prioritizing patient prefer-
ences and quality of life (patient-centred care) was not
identified. The patient-centred care approach aligns with
the current approach to delivering quality health care
services in many countries, including Australia (Institute
of Medicine. Committee on Quality of Health Care in
America 2001; Australian Commission on Safety and
Quality in Health Care 2010). Development of medication-
related quality of care indicators with respect to patient-
centred care warrants further consideration.
Collection and analysis of data for reporting quality of
care indicators can be resource intensive. Experts in
performance measurement in health care rate feasibility,
scientific soundness and relevance as the three most de-
sirable attributes for indicators (National Committe for
Quality Assurance. (Desirable attributes of HEDIS). USA:
www.ncqa.org/tabid/415/Default.aspx Accessed [March
2012). All of the indictors in the minimum indicator set
are operational in that they are currently used in research
and or quality of care reporting systems
Study limitations
The potential for bias in identification and selection of
articles was limited by strictly adhering to predefined
inclusion and exclusion criteria and group consensus on
differences. The PRISMA guidelines were used in both
the study methodology and reporting of the results how-
ever, we cannot rule out that relevant studies or reports
have been missed. We also used the CASP criteria to
ensure that all included articles were of a minimum
quality. Two authors (AV and GC) were deemed suit-
able to oversee and contribute to all steps of this
study as they are experienced in undertaking and
publishing systematic reviews (Spurling et al. 2010;
Caughey et al. 2008).
We also chose a systematic approach to the data
extraction using predefined criteria to minimise bias in
reporting of the qualities of each identified indicator set.
Content analysis methodology has been criticised for
being too reductive and consequently we may have
missed identifying important indicator qualities (Dixon-
Woods et al. 2005).
Every effort was made to correctly designate oper-
ational status to each indicator set. However, many of
the indicator sets are intended for internal quality moni-
toring and reporting and it is possible that some of the
indicators are reported in house or are operational
through incorporation into other datasets.
Only five of the indicators sets identified have been
formally assessed for predictive validity (with varying
results). Further research should focus on investigatingthe relationships between our developed minimum indi-
cator set and health outcomes.
Whilst the identified indicators in our minimum indi-
cator set have content and face validity for medication-
related quality of care in the elderly, many are yet to be
validated for the Australian aged care setting. Indicators
for assessing access to medication-related health services
were not common and may reflect the differences in
health systems between countries. Indicators addressing
medication-related health services specific to residential
aged care residents in Australia, would need to be further
investigated for inclusion in the minimum indicator set.
Subsequent development and validation of the minimum
indicator set should be the focus of future research.Conclusion
In this study we have derived a minimum indicator set for
evaluating medication-related quality of care in residential
aged care using systematically identified and previously
validated indicators based on the key medication-related
needs of the aged care population. The developed mini-
mum indicator set is intended as a starting point for com-
prehensively evaluating medication-related quality of care
in Australian aged care. This study identified that indica-
tors focusing on pertinent medication-related issues for
older aged care residents, namely patient-centred care and
limited life expectancy, were lacking and warrant further
attention. Also, inclusion of additional indicators which
address detection and monitoring of adverse events, not
just falls, as these were not overly prevalent in the indica-
tor sets. The focus on the core medication-related attri-
butes in the minimum indicator set improves the
feasibility of implementation in the aged care setting by
minimising data collection and management. Validation of
the minimum indicator set in the Australian aged care
setting will provide a means to assess and monitor quality
of care in this growing health sector.
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